Furthermore, we observed that patients treated with VEGF-TT in between the resection of their primary RCC and subsequent metastasis had numerically higher c-Met expression in metastatic sites compared to those who did not receive systemic therapy before the resection of the metastases. The gene discussed is MET; the disease is renal cell carcinoma.